Luxembourg Institute of Health

What Luxembourg Institute of Health does

The Luxembourg Institute of Health (LIH) is a public biomedical research organisation established under Luxembourg law (law of 3 December 2014) and headquartered in Strassen, with research operations across Strassen, Luxembourg City, and Esch-sur-Alzette. Founded circa 2015 (with roots traced to 1988 in some firmographic records) and employing 251-500 staff, LIH performs patient-centric translational research with priority focus on cancer and immune-related disorders, treating the immune system as a shared functional module between health and disease. The institute is organised into three research departments (Cancer Research, Infection and Immunity, and Precision Health) and operates the Luxembourg Research Clinic (LCTR – Fuerschungsklinik Lëtzebuerg), which includes a pilot comprehensive cancer center.

LIH's core platform is the Translational Medicine Operations Hub (TMOH), integrating the Clinical Project Management Office (CPMO), Clinical and Epidemiological Investigation Center (CIEC), the ISO 20387-accredited Integrated Biobank of Luxembourg (IBBL), the Disease Modelling & Screening Platform (DMSP), and the Luxgen Genome Center. The institute applies AI on real-world patient-derived data, multi-omics (single-cell proteomics, metabolomics, genomics), biobanking, and disease modelling to translate clinical observations into diagnostics, preventive strategies, and therapies via a bed-to-bench-to-bed approach. Digital health outputs include the Braincoach app for dementia prevention, voice biomarker tools for diabetes and respiratory monitoring, and the LIH Research Portal.

LIH is funded primarily through national public appropriation via the Ministry of Higher Education and Research, competitive grants from the Luxembourg National Research Fund (FNR), European Union research grants (including leadership roles in Clinnova, the EU Mission on Cancer consortium, and brain cancer projects), donations, and investment pathways. It does not sell commercial products in the traditional sense; its 'go-to-market' is the dissemination of research outputs through scientific publications, clinical applications via the Luxembourg Research Clinic, EU project consortia, and translational services to pharma and academic partners. Major collaborations include the QTrobot autism study with LuxAI and the University of Birmingham, an Exobiosphere MoU on space-enabled drug discovery, the Michael J. Fox Foundation's PPMI, and the International Health Data Space Initiative.

Name

Luxembourg Institute of Health

Legal name

Luxembourg Institute of Health

Website

https://lih.lu

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

The Luxembourg Institute of Health (LIH) is a public biomedical research organisation performing patient-centric translational research on cancer, immunological disorders, and precision health for the Luxembourg government, European institutions, and pharma/academic partners, operating a translational medicine hub with biobanking, genomics, and AI-enabled clinical research capabilities.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLACAMAF

Public Health & Reference Lab LIMS

Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

SECONDARYHLACAMAK

Lab Analytics, Utilization Management & Operational Intelligence

Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

SECONDARYHLAHAAAO

Laboratory Informatics for Diagnostics (LIS/Middleware/Analyzer Connectivity)

Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

• Biomedical research services
• Translational medicine
• Clinical research
• Biobanking services
• Precision health

Headquarters

HQ city

Luxembourg

HQ country

Luxembourg

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Public Funding and Government Grants: As a public biomedical research organization under Luxembourg law, LIH is primarily funded through national public funding, government grants, and allocations from Luxembourg's Ministry of Higher Education and Research. Funding also comes from the Luxembourg National Research Fund (FNR).
2. European Research Grants: LIH participates in and leads EU-funded research projects (e.g., EU grants for brain cancer research, immunotherapy, and precision medicine initiatives), providing project-based funding for specific research activities.
3. Donations: The institute accepts donations from individuals, foundations, and organizations to support cancer research and other health research activities. Donors receive tax certificates and are kept informed of research progress.
4. Investment: LIH offers investment pathways for private investors interested in supporting health innovation and translational research outcomes.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Luxembourg Institute of Health (LIH) is a public biomedical research organisation that performs patient-centric translational research focused on cancer and immune-related disorders. It operates dedicated research departments (Cancer Research, Infection and Immunity, Precision Health) and a Translational Medicine Operations Hub (TMOH) that integrates clinical project management, epidemiological investigation, biobanking (IBBL), disease modelling, and genomic services (Luxgen). It also runs the Luxembourg Research Clinic (LCTR – Fuerschungsklinik Lëtzebuerg) as a clinical research facility bridging laboratory science and patient care.

Product overview

LIH is a public biomedical research organization that does not offer commercial software products but provides a comprehensive portfolio of research services, translational medicine infrastructure, and digital health solutions. The core offerings include the Luxembourg Research Clinic (Fuerschungsklinik Lëtzebuerg) and the Translational Medicine Operations Hub (TMOH) comprising the Clinical Project Management Office (CPMO), Clinical and Epidemiological Investigation Center (CIEC), Integrated Biobank of Luxembourg (IBBL), Disease Modelling & Screening Platform (DMSP), and Luxgen Genome Center. Research activities are organized across three main departments: Department of Cancer Research, Department of Infection and Immunity, and Department of Precision Health. Digital health offerings include the Braincoach app for dementia prevention, voice biomarker technologies for health monitoring, and the LIH Research Portal for accessing research information. The institute also coordinates specialized care networks like ParkinsonNet Luxembourg.

Differentiator

Problem solved

Functional benefit

Products and services

• Luxembourg Research Clinic (LCTR – Fuerschungsklinik Lëtzebuerg) A translational medicine research clinic providing clinical research infrastructure and facilities for conducting patient-centered research studies and clinical trials in Luxembourg.
• Integrated Biobank of Luxembourg (IBBL)

Quantifiable outcome

• First large-scale longitudinal study of social robot (QTrobot) for at-home early development support in autistic children, involving 69 families.
• +7 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, notable and flagship.

• LuxAIcoreStrategic or Co-development Partner · 4 December 2025LuxAI, the Luxembourg Institute of Health, and the University of Birmingham jointly launched the world's first large-scale longitudinal study using QTrobot, a social robot, to support early development in autistic children at home. The study involves 69 families in the UK and Luxembourg, aims to evaluate the robot's effectiveness in enhancing communication, social skills, and learning over a 10-month period, and is expected to conclude by the end of 2026. The study is funded by Luxembourg's national research bodies.
• University of BirminghamcoreStrategic or Co-development Partner · 4 December 2025The University of Birmingham is a key academic partner in the QTrobot study, contributing research expertise in child development and autism intervention alongside LIH and LuxAI. The study involves 69 families from the UK and Luxembourg and represents a trilateral international research collaboration.
• ExobiospherenotableStrategic or Co-development Partner · 19 November 2025Exobiosphere and the Luxembourg Institute of Health signed a Memorandum of Understanding (MoU) to advance space-enabled drug discovery. This partnership leverages the unique environment of space for pharmaceutical research and development, combining Exobiosphere's space-enabled capabilities with LIH's biomedical research infrastructure.
• EU Consortium (Brain Cancer Research)flagshipStrategic or Co-development Partner · 4 September 2025LIH was awarded a prestigious EU grant to lead a European research project focused on advancing brain cancer research, involving a consortium of European research institutions working on treatment resistance in glioblastoma and other aggressive brain tumours.
• International Health Data Space Initiative (IHDSI)notableStrategic or Co-development Partner · 22 July 2025LIH participates in the International Health Data Space Initiative (IHDSI), a global partnership launched to accelerate AI-driven precision medicine and cancer research through secure health data sharing across international borders.
• Michael J. Fox FoundationflagshipStrategic or Co-development Partner · 3 July 2024NCER-PD (National Centre of Excellence in Research – Parkinson's Disease), hosted by LIH, joined the prestigious Michael J. Fox Foundation's Parkinson's Progression Markers Initiative (PPMI), positioning Luxembourg's Parkinson's research at the global forefront and enabling international data sharing for Parkinson's disease biomarkers.
• Expon CapitalnotableStrategic or Co-development Partner · 12 July 2023LIH and Expon Capital signed a collaboration agreement to establish a digital health hub in Luxembourg, combining LIH's research infrastructure with Expon Capital's investment and startup ecosystem expertise to accelerate digital health innovation.
• EU Mission on Cancer ConsortiumflagshipStrategic or Co-development Partner · 5 May 2023A new European consortium funded with 6 million Euros, led by LIH, created a network of support for EU Mission on Cancer to improve cancer data quality and timeliness across Europe, including CancerWatch project participation.
• Clinnova ConsortiumflagshipStrategic or Co-development Partner · 27 April 2023The Clinnova consortium, led by LIH, launched a precision medicine initiative across Europe. Clinnova represents a major milestone for health research across Europe, involving multiple partner institutions to advance data-driven precision medicine.
• Advanced BioDesignnotableStrategic or Co-development Partner · 1 July 2020Advanced BioDesign and LIH joined forces to explore new therapeutic strategies for overcoming tumor resistance, combining LIH's translational research capabilities with Advanced BioDesign's therapeutic development expertise.
• Research Luxembourg Coalition (LIH, LISER, LIST, LNS, University of Luxembourg, FNR)flagshipStrategic or Co-development PartnerResearch Luxembourg is a joint initiative of Luxembourg's main public research players coordinated by the Ministry of Higher Education and Research. LIH is a founding member. The coalition coordinates research communication, joint responses to health crises (COVID-19 task force), and cross-institutional research collaboration across Luxembourg's public research sector.
• Think Pink LuxnotableStrategic or Co-development PartnerThink Pink Lux awarded the €30,000 Marian Aldred Award to Nil Karaarslan, a Master's student at LIH, for research into CAR-NK cell immunotherapy for breast cancer. The award supports the study of how cancer cells evade immune detection and how genetically engineered Natural Killer cells can be used to attack tumors.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Others

• Luxembourg Institute of Socio-Economic Research (LISER): Domestic Luxembourg public research counterpart under the same Research Luxembourg coalition. Comparable on public-mandate structure and co-funding arrangements, though focused on socio-economic rather than biomedical research.

Direct peers

• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization in life sciences including genomics, bioinformatics, and translational research. Comparable on public-mandate funding model, multinational scope, and integration of structural biology, genomics, and clinical translation.
• Helmholtz Zentrum München (HMGU): German research center within the Helmholtz Association focused on environmental health, diabetes, and translational medicine. Comparable as a publicly funded biomedical research institute with biobanking, genome center, and clinical cohort capabilities.
• Karolinska Institutet: Sweden's national medical university with a translational medicine focus spanning cancer, immunology, and precision health. Comparable on research scope, public mandate, and integration of clinical investigation with laboratory science.
• Wellcome Sanger Institute: UK-based genomic and biomedical research institute with strong biobanking, sequencing, and disease-cohort programmes. Directly comparable on Luxgen Genome Center / IBBL-style infrastructure and on translational cancer/infection research.
• Francis Crick Institute: UK biomedical discovery institute conducting research across cancer, infection, and immunity with significant translational ambitions. Comparable on translational research focus, public funding base, and integration of genomics, biobanking, and clinical research.
• INSERM (French National Institute of Health and Medical Research): France's national public biomedical research organization with a translational, patient-centric mandate similar to LIH. Directly comparable on mission (public biomedical research under government mandate), structure (multi-institute with laboratory and clinical-investigation units), and funding model (national + EU grants).
• Institut Pasteur: French non-profit foundation with a translational research mandate focused on infectious diseases, immunology, and cancer. Directly comparable on integrated laboratory-to-clinical translation, public-interest mission, and biobank/disease-modelling infrastructure.

Regional players

• Sciensano: Belgian public health and biomedical research institute operating under federal mandate. Comparable as a small-country public biomedical research organization, though with a public-health and epidemiology emphasis rather than LIH's translational-clinic focus.

Broad incumbents

• Charité – Universitätsmedizin Berlin: Europe's largest university hospital with deep translational medicine, clinical trial, and biomedical research operations. Comparable on translational mandate and integration of biobanking, genomics, and clinical research, though at far larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lih-luxembourg
• Xx.com/LIH_Luxembourg
• Facebookfacebook.com/Luxembourg.Institute.of.Health

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luxembourg Institute of Health